Back to search results

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Fallopian Tube Carcinosarcoma · Primary Peritoneal Carcinosarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Clear Cell Adenocarcinoma · Recurrent Fallopian Tube Endometrioid Adenocarcinoma · Recurrent Fallopian Tube High Grade Serous Adenocarcinoma · Recurrent Ovarian Carcinoma · Recurrent Ovarian Carcinosarcoma · Recurrent Ovarian Clear Cell Adenocarcinoma · Recurrent Ovarian Endometrioid Adenocarcinoma · Recurrent Ovarian High Grade Serous Adenocarcinoma · Recurrent Primary Peritoneal Carcinoma · Recurrent Primary Peritoneal Clear Cell Adenocarcinoma · Recurrent Primary Peritoneal Endometrioid Adenocarcinoma · Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma · Recurrent Primary Peritoneal Carcinosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic in Arizona, Scottsdale, Arizona, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Brenda J. Ernst, MD)

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Gerardo Colon-Otero, MD)

  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Matthew S. Block, MD, PhD)
Study leads

  • Matthew S. Block, MD, PhD

    Principal Investigator

    Mayo Clinic in Rochester

View source on ClinicalTrials.gov(opens in a new tab)